Introduction {#section5-1756283X17734116}
============

Upper gastrointestinal bleeding (UGIB) is associated with a markedly increased mortality and morbidity.^[@bibr1-1756283X17734116],[@bibr2-1756283X17734116]^ Despite an improvement in medical care, UGIB is still a common gastrointestinal emergency with an incidence rate of 78 per 100,000 persons annually^[@bibr1-1756283X17734116],[@bibr3-1756283X17734116],[@bibr4-1756283X17734116]^ and a case fatality of about 10 deaths per 100 patients.^[@bibr5-1756283X17734116],[@bibr6-1756283X17734116]^

Risk of UGIB is known to be associated with use of drugs, in particular non-steroidal anti-inflammatory drugs (NSAIDs) and oral anticoagulants.^[@bibr7-1756283X17734116],[@bibr8-1756283X17734116]^ Beta-blockers have a well-documented protective effect on variceal bleeding in cirrhotic patients,^[@bibr9-1756283X17734116]^ and several observational studies have suggested that beta-blocker use is also protective against UGIB in general.^[@bibr10-1756283X17734116][@bibr11-1756283X17734116][@bibr12-1756283X17734116][@bibr13-1756283X17734116][@bibr14-1756283X17734116]--[@bibr15-1756283X17734116]^ However, these were generally small studies, resulting in imprecise results and further did not discriminate between selective and non-selective beta-blockers (see [Supplementary Table 1](http://journals.sagepub.com/doi/suppl/10.1177/1756283X17734116)).

It has been suggested that a gastro-protective effect of beta-blockers on UGIB might be mediated through effects on the secretion of prostaglandins and gastrin.^[@bibr16-1756283X17734116][@bibr17-1756283X17734116]--[@bibr18-1756283X17734116]^ A decrease in the portal venous pressure may also influence the risk of UGIB, as seen in cirrhotic patients with variceal bleeding.^[@bibr19-1756283X17734116][@bibr20-1756283X17734116]--[@bibr21-1756283X17734116]^ However, the exact biological mechanisms behind the suggested protective effect of beta-blockers on non-variceal UGIBs remain uncertain.

As beta-blockers are widely used in the treatment of cardiovascular disease, including hypertension, heart failure, myocardial infarction and stroke, a potential protective effect on UGIBs is important to uncover.^[@bibr22-1756283X17734116]^ In this large population-based case-control study, our aim was to evaluate the suggested protective effect of beta-blockers on UGIB and elucidate possible differences between different types of beta-blockers.

Methods {#section6-1756283X17734116}
=======

This study was a register-based, population-based case-control study. We compared the use of beta-blockers among individuals with UGIB (cases) with the use among individuals without UGIB (controls) to estimate the odds ratio (OR) for UGIB associated with beta-blocker use.

Data sources {#section7-1756283X17734116}
------------

Data were retrieved from three sources: the Danish Central Person Register (CPR), the Funen County Patient Administrative System (FPAS) and Odense Pharmaco-epidemiological Database (OPED). All three registers contain detailed longitudinal data at an individual level. The CPR covers the entire Danish population, while FPAS and OPED cover the population of Funen County (470,000 individuals). All Danish citizens are assigned a unique civil registration number, which is used in all records and enables flawless linkage between registers.^[@bibr23-1756283X17734116],[@bibr24-1756283X17734116]^

The CPR contains information on date of birth, sex, current and historic residency, migrations to and from Denmark and date of death.^[@bibr24-1756283X17734116]^ The data were used to extract controls and to ensure that cases and controls had permanent residence on Funen for at least 365 days prior to their index date.

FPAS holds information on hospital contact among Funen County residents, including discharge diagnoses since 1973. Diagnoses have been encoded by the International Classification of Diseases 10th edition (ICD-10) since 1994.

OPED has information on all reimbursed drug dispensation from Funen County since 1990. Each prescription record includes, among other information, the substance, the date of dispensation, the formulation of the drug and quantity dispensed for each prescription given by number, strength and defined daily dose (DDD).^[@bibr25-1756283X17734116],[@bibr26-1756283X17734116]^ Dosing instructions and indications are not recorded. All drugs are registered according to the Anatomical Therapeutical Chemical (ATC) index.^[@bibr27-1756283X17734116]^ All beta-blockers (ATC: C07) require a prescription.

The dataset has been used and described in detail in a previous study concerning the association between SSRI use and UGIB.^[@bibr28-1756283X17734116]^

Cases and controls {#section8-1756283X17734116}
------------------

Our source population was the residents of Funen County during a study period of 1 August 1995 to 31 July 2006. This population has been shown to be representative of the population in Denmark in general.^[@bibr29-1756283X17734116]^ We included as cases all individuals who fulfilled the following three criteria: (1) admission to a hospital in Funen County within the study period, with peptic ulcer or gastritis as the main diagnosis; (2) mention of melena, a subnormal hemoglobin, or the need for transfusion in the discharge summary or medical record; and (3) a potential bleed source in the stomach or duodenum verified by endoscopy or surgery. Bleedings caused by gastric varices were excluded.

All discharge summaries (*n* = 12,607) with a main diagnosis of peptic ulcer (complicated or not) or gastritis in the study period were manually reviewed in order to include cases coded under less specific diagnoses not indicating bleeding. During the review, the study group was blinded to the exposure status of potential cases. Each case was assigned an index date defined as the first registered date of a UGIB diagnosis.

Controls were selected by risk-set sampling strategy -- that is, for each case we randomly selected 10 controls among the individuals in our source population who matched the case by sex and birth year. Controls were assigned an index date identical to the index date of the corresponding case. We allowed that cases could be selected as controls before they had their case-defining event. Thereby, the calculated OR is an unbiased estimate of the incidence rate ratio that would have emerged from a cohort study, based on the same source population.^[@bibr30-1756283X17734116]^

We required that both cases and controls had been residents of Funen County for at least one year on the index date. We excluded cases and controls with a diagnosis of liver disease before their index date. Patients with liver cirrhosis use unselective beta-blockers as prophylaxis against variceal bleeding and have a strongly elevated risk of peptic ulcer bleeding,^[@bibr31-1756283X17734116]^ thereby constituting a potential confounder. As this exclusion was performed after the matching and as some of the very old cases had fewer than 10 eligible controls, the final control:case ratio deviated slightly from 10:1.

Exposure {#section9-1756283X17734116}
--------

Subjects who had their latest beta-blocker prescription within the past 120 days before or at the index date were categorized as current users. In Denmark, chronic medication is usually dispensed in supplies of 100 days. We added a grace period of 20% to account for minor non-adherence or irregular prescription filling due to stockpiling, thus arriving at a window of 120 days. This assumption was validated by an analysis of the waiting-time distribution.^[@bibr32-1756283X17734116]^ Individuals whose latest beta-blocker prescription was redeemed between 240 and 120 days before the index date were categorized as recent users; individuals whose last beta-blocker prescription was redeemed more than 240 days before the index date were categorized as past users. The reference for all analyses was never-users of beta-blockers.

In supplementary analyses, beta-blockers were subdivided into non-selective (alprenolol, oxprenolol, pindolol, propranolol, timolol, sotalol, tertatolol) and selective (metoprolol, atenolol, acebutolol, betaxolol, bisoprolol). The two combined alpha- and beta-blockers (carvedilol and labetalol) were both classified as non-selective based on the profile of their beta-blocker action.^[@bibr33-1756283X17734116],[@bibr34-1756283X17734116]^

The daily dose of beta-blockers for a treatment episode was calculated by dividing the cumulative number of DDDs dispensed for all prescriptions (except the last) within the episode by the number of days between the first and the last prescription. We considered a chain of successive beta-blocker prescriptions to belong to the same treatment episode if the interval between them never exceeded 120 days (i.e. consistent with our exposure definition). For episodes consisting of only one beta-blocker prescription, the daily dose could not be calculated. The categorization of daily doses (0--0.49, 0.50--0.99 and ⩾1.00 DDD/day) was based on explorative analyses of prescription renewals.

Data analysis {#section10-1756283X17734116}
-------------

By using conditional logistic regression, we estimated the crude and adjusted ORs with 95% confidence intervals (CIs). Confounding by age, sex and calendar time was accounted for by the matching and conditional analysis. For the adjusted ORs, the following potential confounders were included: (1) current use of the following drugs: vitamin K antagonists (VKA), aspirin, other antiplatelet drugs, NSAIDs, selective serotonin reuptake inhibitors (SSRIs), systemic corticosteroids, proton pump inhibitors (PPIs), H2 receptor antagonists, statins, nitrates, spironolactone, calcium antagonists, bisphosphonates; (2) any history of the following events: UGIB, *Helicobacter pylori* (HP) eradication, peptic ulcer, chronic obstructive pulmonary disease (COPD), diabetes, ischemic heart disease, heart failure, stroke, hypertension, inflammatory bowel disease, malignant disease, renal failure; and (3) prescription or diagnosis markers of smoking or excessive alcohol consumption. For all drugs, current drug use was defined by the filling of a prescription within fewer than 120 days before the index date.

For information on codes used to define the covariates, see [Appendix](#app1-1756283X17734116){ref-type="app"}.

Supplementary analyses {#section11-1756283X17734116}
----------------------

In order to appraise the influence of confounding by unmeasured lifestyle covariates, we performed a number of supplementary analyses. We estimated the association between use of beta-blockers (all types) and UGIB within subgroups defined by: (1) any ulcer antecedent (i.e. no history of peptic ulcer or use of anti-ulcer drugs); (2) any use of NSAIDs; (3) any use of antiplatelet drugs; (4) a history of gastrointestinal cancer; (5) any markers of alcohol abuse; and (6) different categories of Charlson score (0, 1--2 and 3 or more).^[@bibr35-1756283X17734116]^ We performed the subgroup analysis stratified on beta-blocker class -- that is, non-selective and selective beta-blockers. Finally, we performed an analysis nested within ever-users of antihypertensives other than beta-blockers (i.e. inhibitors of the renin-angiotensin system, thiazides and related drugs or calcium channel blockers). The rationale was that if the apparent effect of beta-blockers was explained by unmeasured confounders related to the presence of hypertension, this particular analysis would show no association.

All main analyses were carried out independently in duplicate and found to reproduce results accurately.

Others {#section12-1756283X17734116}
------

All analyses were performed using STATA 14.2 (StataCorp, College Station, TX, USA). This study was approved by the Danish Data Protection Agency. According to Danish legislation, neither approval from the ethics committee nor informed consent from the study populations is required for registry-linkage studies.^[@bibr23-1756283X17734116]^

Results {#section13-1756283X17734116}
=======

We identified 3571 UGIB cases and 35,582 controls. Their median age was 75 (interquartile range: 64--83) and 50.7% were male. All included comorbidities and currently used drugs were more common among UGIB cases than controls, as was the use of ulcerogenic medications ([Table 1](#table1-1756283X17734116){ref-type="table"}). As an example, 34.2% of cases were classified as current users of NSAIDs compared with 11.3% of controls.

###### 

Characteristics of cases and controls at the index date.

![](10.1177_1756283X17734116-table1)

  ---------------------------------------------------------------------------------------------
                                Cases\         Controls\                       
                                (*n* = 3571)   (*n* = 35,582)                  
  ----------------------------- -------------- ---------------- -------------- ----------------
  *Age*                                                                        

  Median (IQR)                  75 (64--83)    75 (64--83)      78 (71--84)    75 (62--83)

  *Sex*                                                                        

   Men                          1811 (50.7%)   18,029 (50.7%)   1502 (46.6%)   15,061 (51.7%)

  *Current drug use*                                                           

   VKA                          183 (5.1%)     823 (2.3%)       237 (7.4%)     413 (1.4%)

   Low-dose aspirin             696 (19.5%)    3436 (9.7%)      779 (24.2%)    2109 (7.2%)

   Other antiplatelet drugs     197 (5.5%)     782 (2.2%)       168 (5.2%)     481 (1.7%)

   NSAID                        1220 (34.2%)   4005 (11.3%)     453 (14.1%)    3139 (10.8%)

   SSRI                         429 (12.0%)    2038 (5.7%)      215 (6.7%)     1496 (5.1%)

   Systemic corticosteroids     384 (10.8%)    1638 (4.6%)      150 (4.7%)     1295 (4.4%)

   PPI                          521 (14.6%)    2037 (5.7%)      320 (9.9%)     1395 (4.8%)

   H2 receptor antagonists      294 (8.2%)     958 (2.7%)       105 (3.3%)     732 (2.5%)

   Statins                      237 (6.6%)     1572 (4.4%)      520 (16.1%)    695 (2.4%)

   Nitrates                     318 (8.9%)     1678 (4.7%)      497 (15.4%)    820 (2.8%)

   Spironolactone               208 (5.8%)     599 (1.7%)       110 (3.4%)     380 (1.3%)

   Calcium antagonists          588 (16.5%)    3829 (10.8%)     613 (19.0%)    2363 (8.1%)

   Bisphosphonates              70 (2.0%)      439 (1.2%)       50 (1.6%)      333 (1.1%)

  *History of*                                                                 

   UGIB                         95 (2.7%)      175 (0.5%)       18 (0.6%)      119 (0.4%)

   HP eradication               160 (4.5%)     467 (1.3%)       51 (1.6%)      331 (1.1%)

   Peptic ulcer                 218 (6.1%)     535 (1.5%)       62 (1.9%)      375 (1.3%)

   COPD                         256 (7.2%)     1044 (2.9%)      74 (2.3%)      834 (2.9%)

   Diabetes                     404 (11.3%)    2167 (6.1%)      327 (10.2%)    1533 (5.3%)

   Ischemic heart disease       867 (24.3%)    5272 (14.8%)     1301 (40.4%)   2822 (9.7%)

   Heart failure                279 (7.8%)     1164 (3.3%)      244 (7.6%)     670 (2.3%)

   Stroke                       353 (9.9%)     1835 (5.2%)      250 (7.8%)     1264 (4.3%)

   Hypertension                 412 (11.5%)    1863 (5.2%)      532 (16.5%)    839 (2.9%)

   Inflammatory bowel disease   23 (0.6%)      107 (0.3%)       9 (0.3%)       87 (0.3%)

   Malignant disease            244 (6.8%)     1711 (4.8%)      213 (6.6%)     1318 (4.5%)

   Renal failure                94 (2.6%)      205 (0.6%)       45 (1.4%)      108 (0.4%)

   Alcohol-related markers      166 (4.6%)     336 (0.9%)       32 (1.0%)      271 (0.9%)

   Tobacco-related markers      1148 (32.1%)   8364 (23.5%)     778 (24.2%)    6637 (22.8%)
  ---------------------------------------------------------------------------------------------

COPD, chronic obstructive pulmonary disease; HP, *Helicobacter pylori*; IQR, interquartile range; NSAID, non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitors; SSRI, selective serotonin reuptake inhibitors; UGIB, upper gastrointestinal bleeding; VKA, vitamin K antagonists.

Both ever and current use of beta-blockers were more prevalent among cases than controls (26.9% *versus* 18.1% and 13.6% *versus* 9.1%, respectively). The crude OR for the association between ever-use of beta-blockers and UGIB was 1.70 (95% CI: 1.57--1.85). After adjustment for confounding, use of beta-blockers was not found to be associated with risk of UGIB (adjusted OR 1.10; 95% CI: 1.00--1.21), emphasizing that the increased risk suggested in the crude analysis can be explained by the higher level of comorbidity and polypharmacy among cases. The association remained neutral after stratification by recency, daily dosage, selective and non-selective beta-blockers and the most commonly used single beta-blocker substances ([Table 2](#table2-1756283X17734116){ref-type="table"}).

###### 

Association between use of beta-blockers and UGIB.

![](10.1177_1756283X17734116-table2)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                     Cases\         Controls\        Crude odds ratio (95% CI)   Adjusted odds ratio[\*](#table-fn3-1756283X17734116){ref-type="table-fn"} (95% CI)
                                     (*n* = 3571)   (*n* = 35,582)                               
  ---------------------------------- -------------- ---------------- --------------------------- ------------------------------------------------------------------------------------
  Non-use                            2610           29,121           1.00 (reference)            1.00 (reference)

  Ever-use                           958            6431             1.71 (1.57--1.85)           1.10 (1.00--1.21)

  Beta-blocker class (current use)                                                               

   Selective                         376            2354             1.79 (1.58--2.01)           1.12 (0.97--1.30)

   Metoprolol                        281            1679             1.90 (1.66--2.19)           1.15 (0.97--1.36)

   Atenolol                          61             465              1.37 (1.04--1.80)           1.00 (0.74--1.37)

   Non-selective                     111            886              1.39 (1.13--1.71)           0.85 (0.67--1.08)

   Propranolol                       38             338              1.24 (0.88--1.75)           1.03 (0.71--1.51)

   Carvedilol                        31             173              2.14 (1.43--3.21)           0.77 (0.48--1.25)

  Usage                                                                                          

   Current                           484            3218             1.70 (1.52--1.89)           1.07 (0.94--1.21)

   Recent                            60             388              1.76 (1.32--2.33)           1.25 (0.91--1.72)

   Past                              414            2825             1.66 (1.48--1.86)           1.06 (0.93--1.21)

  Dosage, current use (DDD/day)                                                                  

   0--0.49                           140            1070             1.45 (1.20--1.74)           0.96 (0.77--1.19)

   0.5--1.0                          195            1361             1.60 (1.36--1.88)           0.96 (0.79--1.16)

   \>1.0                             108            614              2.03 (1.63--2.52)           1.32 (1.03--1.69)

   Unknown                           41             173              2.40 (1.68--3.41)           1.48 (0.98--2.23)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ASA, acetylsalicylic acid; COPD, chronic obstructive pulmonary disease; DDD: Defined daily doses; HP, Helicobacter pylori; NSAID, non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitors; SSRI, selective serotonin reuptake inhibitors; UGIB, upper gastrointestinal bleeding; VKA, vitamin K antagonists.

Adjusted for: current use of: VKA, ASA, other antiplatelet drugs, NSAID, SSRIs, systemic corticosteroids, PPIs, H2 receptor antagonists, statins, nitrates, spironolactone, calcium antagonists, bisphosphonates; any history of: UGIB, HP eradication, peptic ulcer, COPD, diabetes, ischemic heart disease, heart failure, stroke, hypertension, inflammatory bowel disease, malignant disease, renal failure; and prescription or diagnosis markers of smoking or excessive alcohol consumption.

The association between current beta-blocker use and UGIB within subgroups is illustrated in [Table 3](#table3-1756283X17734116){ref-type="table"}. Stratifying by age and sex revealed no association. Restricting to non-users of PPI, NSAIDs and antiplatelets, and by the absence of gastrointestinal cancers, ulcer antecedents and alcohol abuse likewise showed no association ([Table 3](#table3-1756283X17734116){ref-type="table"}). Similarly, we found no association among ever-users of antihypertensives other than beta-blockers. Finally, we demonstrated no association within subgroups with different severities of comorbidity assessed by the Charlson score ([Table 3](#table3-1756283X17734116){ref-type="table"}).

###### 

Association between current use of beta-blockers and UGIB within subgroups.

![](10.1177_1756283X17734116-table3)

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Subgroup                               Cases\      Controls\     Crude\              Adjusted [\*](#table-fn5-1756283X17734116){ref-type="table-fn"}\
                                         exposed/\   exposed/\     odds ratio\         odds ratio\
                                         unexposed   unexposed     95% CI              95% CI
  -------------------------------------- ----------- ------------- ------------------- ------------------------------------------------------------------
  All                                    484/2610    3218/29,121   1.70 (1.52--1.89)   1.07 (0.94--1.21)

  Sex                                                                                  

   Men                                   226/1363    1501/15,044   1.69 (1.45--1.98)   0.97 (0.80--1.17)

   Women                                 258/1247    1717/14,077   1.70 (1.47--1.98)   1.16 (0.97--1.38)

  Age (years)                                                                          

   \<55                                  34/350      120/4053      3.23 (2.16--4.83)   1.04 (0.54--1.99)

   55--75                                207/962     1125/11,172   2.14 (1.81--2.52)   1.14 (0.92--1.40)

   \>75                                  243/1298    1973/13,896   1.34 (1.15--1.55)   1.00 (0.84--1.19)

  Drug use                                                                             

   PPI                                   77/361      320/1393      0.96 (0.58--1.58)   0.58 (0.28--1.20)

   No PPI use                            407/2249    2898/27,728   1.69 (1.50--1.90)   1.11 (0.96--1.28)

   NSAID                                 176/884     453/3137      1.27 (0.96--1.66)   0.95 (0.68--1.33)

   No NSAID use                          308/1726    2765/25,984   1.76 (1.53--2.01)   1.09 (0.92--1.28)

   Antiplatelet drugs                    201/430     849/2,306     1.19 (0.98--1.43)   1.17 (0.93--1.47)

   No use of antiplatelet drugs          443/2,546   3120/28,840   1.65 (1.47--1.84)   1.05 (0.92--1.20)

  Medical history                                                                      

   No GI cancer                          444/2,461   3005/27,805   1.69 (1.51--1.89)   1.06 (0.92--1.21)

   No ulcer antecedents                  448/2465    3156/28,748   1.67 (1.49--1.87)   1.05 (0.92--1.20)

   No markers of alcohol abuse           464/2483    3186/28,850   1.69 (1.51--1.89)   1.08 (0.94--1.23)

   Ever use of other antihypertensives   269/698     1639/5491     1.20 (1.00--1.45)   0.99 (0.78--1.25)

  Charlson comorbidity index                                                           

   0                                     228/1477    1975/21,778   1.76 (1.50--2.06)   1.03 (0.85--1.26)

   1--2                                  138/748     871/5708      1.17 (0.91--1.50)   0.88 (0.64--1.22)

   3 or more                             118/385     372/1635      1.68 (1.06--2.65)   1.45 (0.74--2.87)
  -------------------------------------------------------------------------------------------------------------------------------------------------------

ASA, acetylsalicylic acid; COPD, chronic obstructive pulmonary disease; DDD: Defined daily doses; HP, Helicobacter pylori; NSAID, non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitors; SSRI, selective serotonin reuptake inhibitors; UGIB, upper gastrointestinal bleeding; VKA, vitamin K antagonists.

Adjusted for: current use of: VKA, ASA, other antiplatelet drugs, NSAID, SSRIs, systemic corticosteroids, PPIs, H2 receptor antagonists, statins, nitrates, spironolactone, calcium antagonists, bisphosphonates; any history of: UGIB, HP eradication, peptic ulcer, COPD, diabetes, ischemic heart disease, heart failure, stroke, hypertension, inflammatory bowel disease, malignant disease, renal failure; and prescription or diagnosis markers of smoking or excessive alcohol consumption.

For all confounders adjusted for in the analyses, we performed a post-hoc analysis to evaluate the contribution from each of them. Ischemic heart disease was identified as having the largest contribution, as the beta-blocker--UGIB estimate adjusted for this variable alone came closest to the fully adjusted value ([Supplementary Table 2](http://journals.sagepub.com/doi/suppl/10.1177/1756283X17734116)).

Discussion {#section14-1756283X17734116}
==========

In this population-based case-control study, we found no decreased risk of UGIB associated with beta-blocker use, neither overall nor within specific classes or types of beta-blockers. This finding was consistent after stratification by recency and dosage, as well as within subgroups of patients with an increased risk of UGIB.

The association between beta-blocker use and the risk of gastrointestinal bleeding has previously been assessed in six observational studies ([Supplementary Table 1](http://journals.sagepub.com/doi/suppl/10.1177/1756283X17734116)).^[@bibr10-1756283X17734116][@bibr11-1756283X17734116][@bibr12-1756283X17734116]--[@bibr13-1756283X17734116],[@bibr15-1756283X17734116],[@bibr36-1756283X17734116]^ In a case-control study nested among new users of antihypertensive agents, Suissa and colleagues found that use of beta-blockers decreased the risk of gastrointestinal bleeding (adjusted rate ratio (RR) 0.66 (95% CI: 0.44--0.98).^[@bibr12-1756283X17734116]^ Though not statistically significant, the ORs from a case-control study by Lanas and colleagues^[@bibr36-1756283X17734116]^ supported this finding. Similarly, two cohort studies suggested a protective effect of beta-blockers compared with ACE inhibitors or calcium antagonists.^[@bibr11-1756283X17734116],[@bibr15-1756283X17734116]^ A recent study by Nagata and colleagues^[@bibr10-1756283X17734116]^ could not support an association, but the number of exposed cases was very low and confidence intervals wide. Lastly, García Rodriguez and colleagues^[@bibr13-1756283X17734116]^ investigated the association between multiple exposures, including beta-blocker use and verified UGIB. They found an increased risk of UGIB with use of antihypertensive agents (RR: 1.7; 95% CI: 1.4--2.1); however, users of beta-blockers alone were found to have no increased risk of UGIB (RR: 1.0; 95% CI: 0.7--1.4) (see [Appendix](#app1-1756283X17734116){ref-type="app"}). All of these studies were small, including only 4--65 cases exposed to beta-blockers, and did not attempt to differentiate between selective and non-selective beta-blockers. In comparison, we included 484 exposed cases, more than twice the cumulative number from prior studies.

Our study has several important strengths. First and foremost, a manual validation of all cases was performed, thereby minimizing the risk of outcome misclassification. Even admissions that did not specify UGIB were reviewed in order to capture cases that were imprecisely coded. Due to the high quality of our case data, we were able to reproduce all the well-established risk factors for UGIB as demonstrated in [Table 1](#table1-1756283X17734116){ref-type="table"}. Second, our approach was truly population based as Danish health care offers full tax-funded coverage to all citizens and we had access to data on their medical history since 1994 and their drug use since 1990. It is unlikely that patients would suffer severe UGIB without this being captured in our data.

Information bias or confounding by variables not included in this study cannot be fully excluded. First, we did not have data on lifestyle factors that could potentially be confounders. Instead, we used proxies for smoking and excessive alcohol use. Smoking is associated with cardiovascular disease and hence the use of beta-blockers. However, smoking is not a strong risk factor for peptic ulcer bleeding.^[@bibr37-1756283X17734116],[@bibr38-1756283X17734116]^ Excessive drinking is a risk factor for peptic ulcer bleeding.^[@bibr39-1756283X17734116]^ There is no clinical reason to prefer beta-blockers in patients with high alcohol consumption, if they have not developed liver disease. However, if patients with high alcohol consumption use beta-blockers more often than others, this would elevate the OR and might conceal a true protective effect. To this end, we did exclude patients with liver disease as they represent a special subgroup with confounding factors that may be difficult to account for in registry data. Second, we did not have data on use of ulcerogenic over-the-counter (OTC) drugs, such as high-dose aspirin. The prescription coverage of low-dose aspirin and NSAIDs was in the order of 85% and 70% during our study period,^[@bibr40-1756283X17734116]^ but there is no reason to suspect more OTC drug exposure among users of beta-blockers than among others. Though of very high quality, our data are somewhat old. However, this allowed us to analyze the difference between selective and non-selective beta-blockers. The use of non-selective beta-blockers has decreased substantially in recent years,^[@bibr40-1756283X17734116]^ and more recent data would thus contribute little to elucidating the possible effect modification by receptor selectivity. In addition, antithrombotic use has become increasingly complex and aggressive over recent years,^[@bibr41-1756283X17734116]^ thereby leaving more room for confounding.

In conclusion, there was no association between beta-blocker use and serious UGIB in this large population-based study.
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###### 

ATC codes used to define covariates.
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                             ATC code
  -------------------------- -------------------------
  VKA                        B01AA
  ASA                        B01AC06 (excl. B01AC30)
  Other antiplatelet drugs   B01AC (excl. B01AC06)
  NSAIDs                     M01A (excl. M01AX)
  SSRI                       N06AB
  Systemic corticosteroids   H02AB
  PPI                        A02BC
  H2 receptor antagonists    A02BA
  Statins                    C10AA
  Nitrates                   C01DA
  Spironolactone             C03DA01
  Calcium antagonists        C08
  Bisphosphonates            M05BA, M05BB

###### 

ICD-10 codes used to define covariates.
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                               ICD-10 codes
  ---------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stroke                       I60, I61, I62, I63, I64, I65, I66, I67, I69, G45
  Hypertension                 I10, I11, I12, I13, I15
  Inflammatory bowel disease   K50, K51, K528C
  Malignant disease            C (excl. C44, C98), D45, D46, D471, D473, D474, D475
  Renal failure                E102, E112, E122, E132, E142, I12, N01, N03, N083, N085, N118C, N14, N150, N16, N18, N19, N26, P960, Q601, Q602, Z992 (excl. I129 N160 N181)
  Alcohol-related diagnoses    E244, E529A, F10, G312A, G312B, G312C, G312D, G312E, G405B, G621, G721, I426, K292, K70, K860, O354, P043, T519, Z502, Z714, Z721
  Tobacco-related diagnoses    J40, J41, J42, J43, J44, C34
  UGIB                         K250, K252, K254, K256, K260, K262, K264, K266, K270, K272, K274, K276, K280, K282, K284, K286, K290
  Peptic ulcers                K25, K26, K27, K28
  COPD                         J40, J41, J42, J43, J44
  Diabetes                     E10-14, E145D, E891A, G590, G632, G730A, G990C, H280, H360, I792A, M142, N083, O240, O241, O242, O243
  Ischemic heart disease       I200, I201, I201A, I201B, I208, I208A, I209, I210, I211, I212, I212A, I212B, I212C, I212D, I212E, I212F, I212G, I212H, I213, I214, I219, I22, I220, I220A, I220B, I220C, I221, I221A, I221B, I221C, I228, I228A, I228B, I228C, I228D, I228E, I228F, I228G, I228H, I229, I23, I230, I232, I236, I236A, I236B, I238, I241, I252, Z951
  Heart failure                I110, I42, I50, J819
